Therapeutic Group : Cardiovascular Presentation: Metacard MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg. Indications: Metacard MR Tablet is a metabolic treatment for ischaemic heart disease. It can be used at all stages of angina pectoris and in post myocardial infarction. Metacard MR therapy has also demonstrated beneficial effects when administered […]
Therapeutic Group : Intestinal Anti-inflammatory Agent Presentation: Mesagut Tablet: Each delayed release tablet contains Mesalazine BP 400 mg. Indications: – Treatment of mild to moderate Ulcerative Colitis– Maintenance of remission of mild to moderate Ulcerative Colitis– Maintenance of remission of Crohn’s disease Contrainidications: Mesalazine is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates […]
Therapeutic Group : NSAID & Analgesic Presentation: Mervan Tablet: Each film coated tablet contains Aceclofenac BP 100 mg.Mervan SR Tablet: Each sustained release tablet contains Aceclofenac BP 200 mg. Indications: Aceclofenac is indicated for the relief of pain and inflammation of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, low back pain, dental pain, post-traumatic pain etc. Dosage […]
Therapeutic Group : Vitamins & Minerals Presentation: Mecol Tablet: Each film coated tablet contains Mecobalamin INN 0.5 mg. Indications: Peripheral neuropathies (for example, diabetic and alcoholic neuropathy, drug induced neuropathy, lumbago, entrapment neuropathy, intercostal neuralgia and diabetic retinopathy and other neuropathies). Dosage & Administration: Usually for adults, orally administer 1 tablet 3 times a day […]
Therapeutic Group : Antihypertensive Presentation: Maxineb 2.5 Tablet: Each film coated tablet contains Nebivolol Hydrochloride INN equivalent to Nebivolol 2.5 mg.Maxineb 5 Tablet: Each film coated tablet contains Nebivolol Hydrochloride INN equivalent to Nebivolol 5 mg. Indications: Hypertension: Maxineb is indicated for the treatment of hypertension, to lower blood pressure. Maxineb may be used alone […]
Therapeutic Group : Antacid & Antiflatulent Presentation: Maxicon Suspension: Each 5 ml contains Magaldrate USP 480 mg and Simethicone USP 20 mg. Indications: Dyspepsia, hyperacidity, gastritis, flatulence, heartburn & gas. Dosage & Administration: 2-4 teaspoonfuls 20 – 60 minutes after meal and at bedtime or as directed by the physician. Contrainidications: Magaldrate should not be […]
Therapeutic Group : Mydriatic & Cycloplegic Presentation: Matropin Sterile Eye Drops: Each ml contains Homatropine Hydrobromide USP 20 mg. Indications: Matropin Sterile Eye Drops is indicated for use as a mydriatic and cycloplegic agent. Dosage & Administration: For refraction: Instill two drops in the eye(s) and repeat 2-3 times at 5-10 minute intervals. For therapy: […]
Therapeutic Group : Antiulcerant Presentation: Lumeran-150: Each film coated tablet contains Ranitidine Hydrochloride USP equivalent to Ranitidine 150 mg.Lumeran-300: Each film coated tablet contains Ranitidine Hydrochloride USP equivalent to Ranitidine 300 mg. Indications: • Treatment of active duodenal ulcer• Benign gastric ulcer• Treatment & prevention of ulcer associated with non-steroidalanti-inflammatory agent•Post operative stress ulcer.•Zollinger-Ellison Syndrome.•Gastroesophageal […]
Therapeutic Group : anti-inflammatory Presentation: Lotepred® DS Ophthalmic Suspension: Each ml contains Loteprednol Etabonate INN 10 mg. Preservative: Benzalkonium Chloride. Pharmacology: Loteprednol is a corticosteroid which is thought to act by the induction of phospholipase A2 inhibitory proteins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the […]
Therapeutic Group : Antibiotic + Steroid Presentation: Lotepred Plus Sterile Ophthalmic Suspension: Each ml contains Loteprednol Etabonate INN 5 mg and Tobramycin USP 3 mg. Indications: Lotepred-Plus is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. It […]